Пути преодоления резистентности к антигипертензивной терапии у больных артериальной гипертензией: значение доксазозина

И. В. Емельянов; А. О. Конради

doi:10.21518/2079-701X-2014-2-14-17

Пути преодоления резистентности к антигипертензивной терапии у больных артериальной гипертензией: значение доксазозина

И. В. Емельянов, А. О. Конради

https://doi.org/10.21518/2079-701X-2014-2-14-17

Полный текст:

PDF (Rus)

Аннотация

В настоящем кратком обзоре обсуждается роль а-адреноблокаторов, и в частности доксазозина как типичного их представителя, в лечении пациентов с артериальной гипертензией. Подчеркивается значение доксазозина в качестве компонента комбинированной антигипертензивной терапии для преодоления резистентности к лечению. Отдельно обсуждены клинические ситуации, где особенно оправданно применение доксазозина.

Ключевые слова

а-адреноблокаторы, антигипертензивная терапия, артериальное давление, доксазозин, артериальная гипертензия, α-blockers, antihypertensive therapy, hypertension, blood pressure, doxazosin

Об авторах

И. В. Емельянов

ФГБУ «Федеральный медицинский исследовательский центр имени В.А. Алмазова» Минздрава России, Санкт-Петербург
Россия

А. О. Конради

Список литературы

1. Chobanian AV, Bakris GL, Black HR et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report.JAMA. 2003, 289: 560-2572.

2. Chapman N, Chang CL, Dahlof B et al. Effect of doxazosingastrrointestinal therapeutic system as third line antihypertensive therapy on BP and lipids in the AngloScandinavian Cardiac Outcomes Trial. Circulation. 2008, 188: 42-48.

3. Matsui YL, Eguchi K, Shibasaki S et al. Effect of doxazosin on the left ventricular structure and function in morning hypertensive patients: the Japan Morning Surge 1 study. J Hypertens. 2008, 26, 7: 1463-1471.

4. Spoladore RL, Roccaforte R, Fragasso G et al. Safety and efficacy of doxazosin as an «add-on» antihypertensive therapy in mild to moderate heart failure patients. Acta Cardiol. 2009, 64, 4, 485-91.

5. Rodilla E, Costa JA, Perez-Lahiguera F et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev. Esp. Cardiol 2009. 62: 158-166.

6. Elliott WJ. Management of Resistant hypertension. Curr. Cardiovasc. Rep. 2011, 5: 373-382.

7. Chapman NI, Chen CY, Fujita T et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens. 2010, 28, 9: 1796-1803.

8. Conzo G, Musella M, Corcione F, De Palma M. Role of Preoperative Adrenergic Blockade with Doxazosin on Hemodynamic Control during the Surgical Treatment of Pheochromocytoma: A Retrospective Study of 48 Cases. American Surgeon. 2013, 79: 1196-1202.

9. Mazza A, Armigliato M, Marzola MC et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrin. 2013. Epub 4 Jul 2013. doi 10.1007/s 12020-013-0007-y.

10. Shao Y, Chen R, Shen CJ et al. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary? J Hypertens, 29 (12): 2429-32.

11. Zhu Yu, He H, Su T et al. Selective a1-adrenoreceptors antagonists (controlled released tablets) in preoperative management of pheochromocytoma. Endocr. 2010, 38: 254-259.

12. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observation on concomitant hypertension. Scand J Urol Nephrol. Suppl. 1995. 168: 7-12.

13. Lee SH, Park KK, Mah S, Chung BH. Effects of a-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. Prostate Cancer and Prostatic Diseases. 2010, 13: 333-337.

14. Guzik PL, Wykretowicz A, Krauze T, Piskorski J et al. Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: effects on autonomic modulation of the cardiovascular system. Hypertens Res. 2008, 31, 3: 443-453.

15. Calhoun DA, Jones D, Textor S et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Circulation, 2008, 117: 510-526.

16. Fagard RH. Resistant hypertension. Heart. 2012, 98: 254-261.

17. Esler M, Krum H, Schlaich M. Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial. Circulation. 2012, 126: 2976-2982.

18. Lohmeier T, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation. Mechanisms and potential for hypertension therapy. Hypertension. 2011, 57: 880-886.

19. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии. 2010, 3: 23-27.

20. ESH/ESC Guidelines for the Management of Arterial Hypertension. The Task Force for the management of arterial hypertension of European Society of Hypertension (ESH) and European Society of Cardiology (ESC).J. Hypertens. 2013, 31: 1281-1357.

21. Guidelines Subcommittee. 1999 World Health Organization - International Society of Hypertension. Guidelines for the Management of Hypertension. J. Hypertens. 1999, 17: 151-183. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA. 2000, 283: 1967-1975.

22. Zanchetti A et al. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003, 21: 1011-1053